Pricing key to success of MS drug Aubagio in India, says analyst

28 August 2018

Sanofi Genzyme, the specialty care global business unit of French multinational pharma company Sanofi (Euronext: SAN), has recently launched its multiple sclerosis (MS) drug Aubagio (teriflunomide, 14mg) in India.

However, the company needs to be wary of the fierce generic competition and cost sensitivity of the Indian market, cautions data and analytics company GlobalData.

Aubagio offers MS patients a convenient treatment option of ‘once-daily’ oral tablet vis-à-vis commonly available as injectable treatment options, claims the company. The drug was first approved by the US Food and Drug Administration in 2012 and is currently approved in more than 80 countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK